OncoMatch/Clinical Trials/NCT06783790
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Is NCT06783790 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Avapritinib, azacitidine, Venetoclax for aml (acute myelogenous leukemia).
Treatment: Avapritinib, azacitidine, Venetoclax — This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation with C-KIT mutation RUNX1::RUNX1T1 or CBFB::MYH11.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KIT D816 mutation
Bone marrow molecular biology detected C-KIT D816 or C-KIT N822 mutations
Required: KIT N822 mutation
Bone marrow molecular biology detected C-KIT D816 or C-KIT N822 mutations
Required: CBFB CBFB::MYH11 fusion gene
Patients with CBFB::MYH11 gene detected
Required: RUNX1 RUNX1::RUNX1T1 fusion gene
Patients with RUNX1::RUNX1T1 fusion gene detected
Excluded: FLT3 ITD mutation
FLT3-ITD mutation in patients with recurrent/refractory disease (except low gene ratio)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic stem cell transplant
recurrence after allogeneic transplantation
Cannot have received: KIT inhibitor (Midostaurin)
Patients who have received previous treatment with Midostaurin
Cannot have received: mutation-specific KIT inhibitor
Exception: except if no disease progression during treatment
Patients who have previously been treated with mutation-specific C-KIT inhibitors and have developed disease progression during treatment
Lab requirements
Kidney function
creatinine ≤1.5 upper limit of normal value
Liver function
Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; Myocardial enzymes < 2 times the upper limit of normal (for the same age)
Cardiac function
Left ventricular ejection fraction ≥50%; Blood oxygen saturation >91%
Liver, kidney and cardiopulmonary functions met the following requirements: Within 2 weeks before enrollment ① creatinine ≤1.5 upper limit of normal value; ② Left ventricular ejection fraction ≥50%; ③ Blood oxygen saturation >91%; ④ Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; Myocardial enzymes < 2 times the upper limit of normal (for the same age)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify